Works matching AU Bilic, Sanela

Results: 12

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.
Published in:
BMC Clinical Pharmacology, 2008, v. 8, p. 1, doi. 10.1186/1472-6904-8-2
By:
- Spencer, Andrew;
- Roberts, Andrew;
- Kennedy, Nola;
- Ravera, Christina;
- Cremers, Serge;
- Bilic, Sanela;
- Neeman, Terry;
- Copeman, Michael;
- Schran, Horst;
- Lynch, Kevin
Publication type:
Article
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Published in:
British Journal of Haematology, 2014, v. 167, n. 3, p. 366, doi. 10.1111/bjh.13056
By:
- Iyer, Swaminathan P.;
- Beck, Joseph Taddeus;
- Stewart, A. Keith;
- Shah, Jatin;
- Kelly, Kevin R.;
- Isaacs, Randi;
- Bilic, Sanela;
- Sen, Suman;
- Munshi, Nikhil C.
Publication type:
Article
A phase 1 study of lucatumumab, a fully human anti- CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.
Published in:
British Journal of Haematology, 2012, v. 159, n. 1, p. 58, doi. 10.1111/j.1365-2141.2012.09251.x
By:
- Bensinger, William;
- Maziarz, Richard T.;
- Jagannath, Sundar;
- Spencer, Andrew;
- Durrant, Simon;
- Becker, Pamela S.;
- Ewald, Brett;
- Bilic, Sanela;
- Rediske, John;
- Baeck, Johan;
- Stadtmauer, Edward A.
Publication type:
Article
Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.
Published in:
Journal of Clinical Pharmacology, 2017, v. 57, p. S105, doi. 10.1002/jcph.908
By:
- Bullock, Julie M.;
- Lin, Tiffany;
- Bilic, Sanela
Publication type:
Article
Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones.
Published in:
Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-47271-y
By:
- Denisenko, Elena;
- de Kock, Leanne;
- Tan, Adeline;
- Beasley, Aaron B.;
- Beilin, Maria;
- Jones, Matthew E.;
- Rui Hou;
- Muirí, Dáithí Ó.;
- Bilic, Sanela;
- Mohan, G. Raj K. A.;
- Salfinger, Stuart;
- Fox, Simon;
- Hmon, Khaing P. W.;
- Yen Yeow;
- Youngmi Kim;
- John, Rhea;
- Gilderman, Tami S.;
- Killingbeck, Emily;
- Gray, Elin S.;
- Cohen, Paul A.
Publication type:
Article
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.
Published in:
Leukemia & Lymphoma, 2012, v. 53, n. 11, p. 2136, doi. 10.3109/10428194.2012.681655
By:
- Byrd, John C.;
- Kipps, Thomas J.;
- Flinn, Ian W.;
- Cooper, Maureen;
- Odenike, Olatoyosi;
- Bendiske, Jennifer;
- Rediske, John;
- Bilic, Sanela;
- Dey, Jyotirmoy;
- Baeck, Johan;
- O'Brien, Susan
Publication type:
Article
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
Published in:
Investigational New Drugs, 2014, v. 32, n. 1, p. 135, doi. 10.1007/s10637-013-9952-9
By:
- Sharma, Sunil;
- Vries, Elisabeth;
- Infante, Jeffrey;
- Oldenhuis, Corina;
- Gietema, Jourik;
- Yang, Lin;
- Bilic, Sanela;
- Parker, Katie;
- Goldbrunner, Michael;
- Scott, Jeffrey;
- Burris, Howard
Publication type:
Article
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.
Published in:
2015
By:
- Papadopoulos, Kyriakos P;
- Isaacs, Randi;
- Bilic, Sanela;
- Kentsch, Kerstin;
- Huet, Heather A;
- Hofmann, Matthias;
- Rasco, Drew;
- Kundamal, Nicole;
- Tang, Zhongwhen;
- Cooksey, Jennifer;
- Mahipal, Amit
Publication type:
journal article
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody targeting the DR5 receptor.
Published in:
Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 5, p. 887, doi. 10.1007/s00280-015-2712-0
By:
- Papadopoulos, Kyriakos;
- Isaacs, Randi;
- Bilic, Sanela;
- Kentsch, Kerstin;
- Huet, Heather;
- Hofmann, Matthias;
- Rasco, Drew;
- Kundamal, Nicole;
- Tang, Zhongwhen;
- Cooksey, Jennifer;
- Mahipal, Amit
Publication type:
Article
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy.
Published in:
2021
By:
- Barrett, Doreen;
- Bilic, Sanela;
- Chyung, Yung;
- Cote, Shaun M.;
- Iarrobino, Ryan;
- Kacena, Katherine;
- Kalra, Ashish;
- Long, Kimberly;
- Nomikos, George;
- Place, Amy;
- Still, James Gordon;
- Vrishabhendra, Leela
Publication type:
journal article
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
Published in:
mAbs, 2014, v. 6, n. 6, p. 1560, doi. 10.4161/19420862.2014.975099
By:
- Huet, Heather A;
- Growney, Joseph D;
- Johnson, Jennifer A;
- Li, Jing;
- Bilic, Sanela;
- Ostrom, Lance;
- Zafari, Mohammad;
- Kowal, Colleen;
- Yang, Guizhi;
- Royo, Axelle;
- Jensen, Michael;
- Dombrecht, Bruno;
- Meerschaert, Kris RA;
- Kolkman, Joost A;
- Cromie, Karen D;
- Mosher, Rebecca;
- Gao, Hui;
- Schuller, Alwin;
- Isaacs, Randi;
- Sellers, William R
Publication type:
Article
American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates.
Published in:
mAbs, 2013, v. 5, n. 1, p. 1, doi. 10.4161/mabs.22909
By:
- Thudium, Karen;
- Bilic, Sanela;
- Leipold, Douglas;
- Mallet, William;
- Kaur, Surinder;
- Meibohm, Bernd;
- Erickson, Hans;
- Tibbitts, Jay;
- Zhao, Hong;
- Gupta, Manish
Publication type:
Article